This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing therapeutics in development for melanoma including Moderna/Merck's mRNA-4157 cancer vaccine and Iovance Biotherapeutics' TIL therapy, lifileucel.

Ticker(s): MRNA, IOVA, MRK

Who's the expert?

  • Assistant Professor in the Department of Internal Medicine major US academic medical center.
  • Treats more than 100 melanoma patients per year.
  • Clinical speciality in cutaneous and non-cutaneous melanoma, advanced skin cancer, and soft tissue malignancies; Research interest in immunotherapy with clinical trials in melanoma.

Interview Goal
On this call we will be digging in to the Phase 2b KEYNOTE-942 data presented at the 2023 AACR Annual Meeting of Moderna's mRNA-4157, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor, pembrolizumab, in patients with high-risk melanoma. We will also be discussing Iovance Biotherapeutics' tumor infiltrating lymphocyte(TIL) therapy, lifileucel.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.